Das Geld flieht:
Das ist kein Gold-Boom, das ist ein Systembruch – und er hat gerade erst begonnen
Anzeige
HALOZYME WKN: A0DLHS ISIN: US40637H1095 Kürzel: HALO Forum: Aktien Thema: Hauptdiskussion
56,37
EUR
+2,77 % +1,52
16:24:06 Uhr,
Lang & Schwarz
Kommentare 165
Blacksheep,
05.08.2025 22:26 Uhr
1
Liest sich auch gut in der Kurzform😎
Halozyme Therapeutics press release (NASDAQ:HALO): Q2 Non-GAAP EPS of $1.54 beats by $0.31.
Revenue of $325.7M (+40.8% Y/Y) beats by $39.78M.
https://seekingalpha.com/news/4479053-halozyme-therapeutics-non-gaap-eps-of-1_54-beats-by-0_31-revenue-of-325_7m-beats-by-39_78m
Shareholder1909,
05.08.2025 23:42 Uhr
0
"Halozyme überzeugt mit Quartalsergebnis und erhöht Jahresprognose"
https://de.investing.com/news/earnings/halozyme-uberzeugt-mit-quartalsergebnis-und-erhoht-jahresprognose-93CH-3098490
Shareholder1909,
4. Nov 16:17 Uhr
0
"Halozyme Q3 2025: Lizenzeinnahmen steigen um 52 %, Prognose nach starkem Wachstum erhöht"
https://de.investing.com/news/company-news/halozyme-q3-2025-lizenzeinnahmen-steigen-um-52--prognose-nach-starkem-wachstum-erhoht-93CH-3214378
Shareholder1909,
4. Nov 16:17 Uhr
1
"Citizens hebt Kursziel für Halozyme auf 92 Dollar an – starkes Lizenzwachstum als Treiber"
https://de.investing.com/news/analyst-ratings/citizens-hebt-kursziel-fur-halozyme-auf-92-dollar-an--starkes-lizenzwachstum-als-treiber-93CH-3215207
Shareholder1909,
05.08.2025 22:17 Uhr
0
Additionally, the GAAP Diluted EPS saw an 85% increase year-over-year to $1.33, while Non-GAAP Diluted EPS increased by 69% year-over-year to $1.54. The company also raised its full-year 2025 financial guidance, projecting total revenue to be in the range of $1,275 to $1,355 million, reflecting a year-over-year growth of 26% to 33%. Adjusted EBITDA guidance was also increased to a range of $865 to $915 million, indicating a growth of 37% to 45% year-over-year. Non-GAAP Diluted EPS is now anticipated to be between $6.00 and $6.40, representing a growth of 42% to 51% year-over-year.
Shareholder1909,
05.08.2025 22:15 Uhr
0
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.23 by 25.2 percent. This is a 69.23 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $325.719 million which beat the analyst consensus estimate of $281.588 million by 15.67 percent. This is a 40.79 percent increase over sales of $231.353 million the same period last year.
Ben_M,
13.05.2025 18:02 Uhr
0
Halozyme hat erst vor wenigen Wochen die Guidance erneut angehoben ...
Ben_M,
13.05.2025 17:37 Uhr
0
Downgrade von Halozyme und J&J durch Leerink Partners aufgrund von Unsicherheiten hinsichtlich des Centers for Medicare & Medicaid Services und möglichen Preisdeckeln
Anakin,
07.05.2025 16:07 Uhr
0
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 https://www.prnewswire.com/news-releases/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-first-quarter-2025-results-302447541.html
Starke zahlen 💪
Blacksheep,
07.05.2025 6:28 Uhr
0
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase
Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million
Net Income Increased 54% YOY to $118 million; GAAP Diluted EPS Increased 55% YOY to $0.93;
non-GAAP Diluted EPS Increased 41% YOY to $1.111
Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%,
and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1
https://www.prnewswire.com/news-releases/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-first-quarter-2025-results-302447541.html
Blacksheep,
19.02.2025 10:33 Uhr
0
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million
Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261
https://www.prnewswire.com/news-releases/halozyme-reports-full-year-2024-record-revenue-of-1-015-billion-and-exceeds-its-financial-guidance-for-royalty-revenue-adjusted-ebitda-and-non-gaap-diluted-eps-302379289.html
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Security der nächsten Generation | +5,11 % | |
| 2 | Canopy Hauptforum | +13,38 % | |
| 3 | NVIDIA Hauptdiskussion | -1,76 % | |
| 4 | Quantum Emotion, redefrei | +5,11 % | |
| 5 | ORACLE Hauptdiskussion | -4,52 % | |
| 6 | Dax Prognose | -0,22 % | |
| 7 | für alle, die es ehrlich meinen beim Traden. | ||
| 8 | BioNTech Hauptdiskussion | +0,89 % | |
| 9 | IROBOT Hauptdiskussion | +35,25 % | |
| 10 | Rezolve Ai Hauptdiskussion | -12,57 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | Security der nächsten Generation | +5,32 % | |
| 2 | Canopy Hauptforum | +14,01 % | |
| 3 | NVIDIA Hauptdiskussion | -1,70 % | |
| 4 | Quantum Emotion, redefrei | +5,32 % | |
| 5 | ORACLE Hauptdiskussion | -4,66 % | |
| 6 | BioNTech Hauptdiskussion | +0,25 % | |
| 7 | IROBOT Hauptdiskussion | +38,58 % | |
| 8 | Rezolve Ai Hauptdiskussion | -11,15 % | |
| 9 | RHEINMETALL Hauptdiskussion | +2,78 % | |
| 10 | The Cannabist (Hauptforum) | +4,79 % | Alle Diskussionen |